Hikal Ltd
Hikal Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Pharma volumes expected to return to double-digit growth next year after minor delays in FY '26 due to FDA impact. FY '27 is expected to mark the start of significant growth after a delayed recovery due to prior regulatory impacts; pharma segment growth will pick up strongly from early FY '27 onwards.
From Hikal Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Pharma volumes expected to return to double-digit growth next year after minor delays in FY '26 due to FDA impact.
- Q3 FY '26 pharma volumes grew about 4%; strong recovery anticipated in H2 FY '26 and FY '27 onward.
- Crop Protection business expected to remain flattish in FY '26; pricing pressures persist but stabilization expected.
- New pharma products launching in FY '27 (second half) and Animal Health ramp-up by FY '28, driving growth.
- Animal Health targeted to be INR 500 crores+ business in 4-5 years; volumes ramping up commercially over next 2 quarters.
- Specialty Chemicals (Personal Care) segment to commercialize 3-4 products in FY '27, adding a new growth lever.
- Overall growth to improve from FY '27 as remediation concludes and new product pipelines mature.
- EBITDA margins expected to improve due to better fixed cost absorption and higher-margin new products.
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex targeted at ~INR150 crores, down from initial guidance of INR200 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacities.
- INR100 crores spent in first 9 months of FY '26; additional INR40-50 crores expected in Q4 FY '26.
- Investment in a high-potency laboratory (Phase I) of about INR10-11 crores completed; commercial scale plant planned in FY '28.
- Phased repurposing of crop protection plant over next 6-18 months based on customer contracts, involving limited capex mostly for reactors and pipelines.
- Expansion of pilot scale capacity at Pune R&D centre underway for growing CDMO pipeline.
- Future capex post FY '26 expected to be modest with focus on adding specific lines or plants as per customer demand; major new capex unlikely.
- Capex strategy prioritizes high-ROI, targeted projects aligned with long-term growth.
- From FY '29 onwards, reduced overall debt expected as cash flows improve and capex tapers off.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order pipeline in the pharmaceutical segment is robust and growing, with a significant number of Request for Proposals (RFPs), particularly from global innovators and emerging biotech firms.
- Several key programs are advancing from lab to development and scale-up phases, improving medium-term revenue visibility.
- The Crop Protection division is seeing a quick uptick in order inflow and inquiries due to recovery in end-customer volumes, despite competitive pricing.
- Expansion into new geographical markets (Europe, Latin America, Middle East) is strengthening global presence and supporting order book growth.
- New product commercializations in Personal Care and Animal Health segments are expected to add to order volume over the next 9 to 12 months.
- Repurposing of crop protection plants is aligned to customer contracts, with phased execution planned over 6 to 18 months based on confirmed orders.
- Overall, the company anticipates order inflows to resume strongly as global uncertainties ease and new capacities come online.
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Hikal Ltd Q3 FY26 results?
Pharma volumes expected to return to double-digit growth next year after minor delays in FY '26 due to FDA impact. FY '27 is expected to mark the start of significant growth after a delayed recovery due to prior regulatory impacts; pharma segment growth will pick up strongly from early FY '27 onwards.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
FY '26 capex targeted at ~INR150 crores, down from initial guidance of INR200 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacities.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.